Opinion Statement The majority of patients with esophagogastric cancer present with
advanced disease, which is incurable. Systemic chemotherapy can lead to a decrease in …

Although combination chemotherapy has been shown to be more effective than single
agents in advanced esophagogastric cancer, the better response rates have not fulfilled …

Gastric cancer is the fourth most common malignancy and second leading cause of cancer
death world-wide, and is therefore a significant global health problem. Radical surgery with …

Opinion statement Gastric and gastroesophageal junction (GEJ) cancers represent the third
leading cause of malignancy-associated death worldwide. Approximately 15–20% of these …

Identification of the importance of human epidermal growth factor receptor-2 (HER2) status,
biomarker testing and the development of anti-HER2 treatments have changed the …

The prognostic value of human epidermal growth factor receptor 2 (HER2) in gastric cancer
is controversial. Consensus guidelines have standardized the testing of HER2 status in …

The addition of trastuzumab to the treatment of a subset of patients with advanced gastric
and gastroesophageal junction cancers showing HER2 positivity has been shown to confer …

Recent advances in molecular targeted therapies, including targeting human epidermal
growth factor receptor 2 (HER2), had a major forward step in the therapy for gastric cancer …

MSI high gastric cancer has a better prognosis and may not require adjuvant chemotherapy.
Trastuzumab, added to preoperative chemoradiotherapy in HER2-positive esophageal …

Surgery is the only curative therapy for gastric cancer. In the metastatic setting the objective
of treatment is to manage symptoms, improve quality of life and prolong survival, but current …